Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.40 EUR
Change Today +0.031 / 1.31%
Volume 0.0
RN3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (RN3) Snapshot

Open
€2.30
Previous Close
€2.37
Day High
€2.42
Day Low
€2.30
52 Week High
01/14/15 - €5.19
52 Week Low
08/26/15 - €2.24
Market Cap
581.1M
Average Volume 10 Days
60.0
EPS TTM
--
Shares Outstanding
242.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARENA PHARMACEUTICALS INC (RN3)

arena pharmaceuticals inc (RN3) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (RN3) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company’s products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

325 Employees
Last Reported Date: 03/2/15
Founded in 1997

arena pharmaceuticals inc (RN3) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $746.8K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $441.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $415.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $394.0K
Compensation as of Fiscal Year 2014.

arena pharmaceuticals inc (RN3) Key Developments

Arena Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Arena Pharmaceuticals reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter 2015, the company reported revenues of $9.2 million compared to $12.8 million for the second quarter 2014. Second quarter 2015 revenues included $4.3 million from net product sales of BELVIQ; $1.2 million in reimbursements from Eisai, primarily for clinical trial supply for the ongoing CVOT study and development work for the once-daily formulation; and $2.1 million from amortization of upfront payments. Net loss was $26.807 million or $0.11 per share on a fully diluted basis compared to net income of $7.480 million for the second quarter of 2014 or $0.03 per share, fully diluted. The net income in the second quarter of 2014 included a onetime gain of $33.3 million related to its sale of shares the company held at TaiGen Biotechnology Company Limited. For the six months, the company reported total revenues of $21.437 million compared to $19.615 million a year ago. Net loss was $51.102 million or $0.21 per basic and diluted share compared to $17.775 million or $0.08 per basic and diluted share a year ago.

Arena Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Arena Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 05, 2015

Arena Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Arena Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RN3:GR €2.40 EUR +0.031

RN3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $5.94 USD +0.10
Orexigen Therapeutics Inc $2.89 USD +0.13
Progenics Pharmaceuticals Inc $7.67 USD -0.16
Rigel Pharmaceuticals Inc $2.99 USD +0.12
Spectrum Pharmaceuticals Inc $7.60 USD +0.11
View Industry Companies
 

Industry Analysis

RN3

Industry Average

Valuation RN3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.9x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.